RNA-lipid particles comprising polysarcosine-lipid conjugate
Polysarcosine-lipid conjugates in RNA-lipid particles address the limitations of PEGylation in mRNA delivery by enhancing cellular uptake and stability, improving biological activity and safety without immune response.
WO2025061153A9PCT designated stage expired Publication Date: 2026-06-04EVEREST MEDICINES (CHINA) CO LTD +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2024/120060
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-22
- Filing Date
- 2024-09-20
- Publication Date
- 2026-06-04
Smart Images
Figure PCTCN2024120060-FTAPPB-I100001 
Figure PCTCN2024120060-FTAPPB-I100002 
Figure PCTCN2024120060-FTAPPB-I100003
Abstract
Provided are RNA-lipid particles and formulations comprising novel lipids and therapeutic agents, methods of preparing RNA-lipid particles, and methods of delivering and / or administering RNA-lipid particles. In particular, provided are RNA-lipid particles comprising a polysarcosine-based lipid conjugate or a conjugate of polysarcosine and lipid-like material, and RNA such as single-stranded messenger RNA which encodes a peptide or protein of interest, and methods of preparing the RNA-lipid particles. The particles comprising mRNA and polysarcosine are delivered to target tissues after administered via intramuscular, intravenous, or subcutaneous route.
Need to check novelty before this filing date? Find Prior Art